And the conspicuous omission of the NASH and PNAFLD programs in today's prospectus only heightens the concern. Have we seriously scrapped a a fully-funded NIH trial in PNAFLD with results due in a few months? Where is the explanation? Immuron is horrendous with communication to shareholders.
And the conspicuous omission of the NASH and PNAFLD programs in...
Add IMC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.001(1.01%) |
Mkt cap ! $22.8M | |||
| Open | High | Low | Value | Volume |
| 9.9¢ | 10.0¢ | 9.9¢ | $21.40K | 214.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10653 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 207757 | 9 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
10.0¢ |
Change
0.001 ( 1.01 %) |
||||
| Open | High | Low | Volume | ||
| 10.0¢ | 10.0¢ | 9.9¢ | 53043 | ||
| Last updated 12.15pm 03/05/2024 ? | |||||
| IMC (ASX) Chart |